Next Article in Journal
Error Propagation Analysis for Quantitative Intracellular Metabolomics
Next Article in Special Issue
Glycomics Approaches for the Bioassay and Structural Analysis of Heparin/Heparan Sulphates
Previous Article in Journal
Metabolic Consequences of TGFb Stimulation in CulturedPrimary Mouse Hepatocytes Screened from Transcript Data with ModeScore 
Previous Article in Special Issue
Comparative Analysis of End Point Enzymatic Digests of Arabino-Xylan Isolated from Switchgrass (Panicum virgatum L) of Varying Maturities using LC-MSn
Metabolites 2012, 2(4), 1004-1011; doi:10.3390/metabo2041004
Review

Glycomic Expression in Esophageal Disease

,
 and
*
Henry Ford Hospital, 2799 W. Grand Blvd., Detroit, MI 48202, USA
* Author to whom correspondence should be addressed.
Received: 25 September 2012 / Revised: 5 November 2012 / Accepted: 9 November 2012 / Published: 21 November 2012
(This article belongs to the Special Issue Glycomics and Glycoproteomics)
View Full-Text   |   Download PDF [177 KB, uploaded 21 November 2012]

Abstract

Glycosylation is among the most common post translation modifications of proteins in humans. Decades of research have demonstrated that aberrant glycosylation can lead to malignant degeneration. Glycoproteomic studies in the past several years have identified techniques that can successfully characterize a glycan or glycan profile associated with a high-grade dysplastic or malignant state. This review summarizes the current glycomic and glycoproteomic literature with specific reference to esophageal cancer. Esophageal adenocarcinoma represents a highly morbid and mortal cancer with a defined progression from metaplasia (Barrett's esophagus) to dysplasia to neoplasia. This disease is highlighted because (1) differences in glycan profiles between the stages of disease progression have been described in the glycoproteomic literature; (2) a glycan biomarker that identifies a given stage may be used as a predictor of disease progression and thus may have significant influence over clinical management; and (3) the differences in glycan profiles between disease and disease-free states in esophageal cancer are more dramatic than in other cancers.
Keywords: esophageal adenocarcinoma; glycomics; glycoproteomics; biomarkers; cancer esophageal adenocarcinoma; glycomics; glycoproteomics; biomarkers; cancer
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Mohanty, S.; Tsiouris, A.; Hammoud, Z. Glycomic Expression in Esophageal Disease. Metabolites 2012, 2, 1004-1011.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Metabolites EISSN 2218-1989 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert